Use of platelet-rich autoplasma in the assisted reproductive technology programs
Zabrodina Y. Akhmediyanova G.U. Khamidullina Z.G.
2023Bionika Media Ltd.
Akusherstvo i Ginekologiya (Russian Federation)
2023#2023Issue 75 - 11 pp.
To date, the use of platelet-rich autoplasma (PRA) has become one of the new areas used in the assisted reproductive technology programs. Platelets contain a large number of growth factors and different types of proteins that are released after their activation. These factors accelerate cell mitosis, promote angiogenesis of endothelial cells, induce anti-inflammatory modulators, and support the production of fibrinogen that is essentially a framework for tissue regeneration. The intraovarial and intrauterine PRA administration has been used in reproductive medicine for the thin endometrium, premature ovarian insufficiency, and a low ovarian reserve. In preparing this review, we sought literature over the past 10 years to identify studies on the use of PRA therapy in the assisted reproductive technology programs. Conclusion: The use of PRA is a new and rather promising method for infertility treatment in some women who are resistant to standard therapy. However, there is a need for additional prospective randomized controlled trials involving more participants to more significantly demonstrate the benefits of PRA therapy in clinical practice.
Assisted reproductive technologies , In vitro fertilization , Platelet-rich plasma , PRA and low ovarian reserve , PRA and thin endometrium , PRA therapy
Text of the article Перейти на текст статьи
Medical University of Astana, Astana, Kazakhstan
Astana Medical University, Saryarka str., 11, 126, Astana, 010000, Kazakhstan
Obstetrics and Gynecology Department One, Astana Medical University, Astana, Kazakhstan
Medical University of Astana
Astana Medical University
Obstetrics and Gynecology Department One
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026